论文部分内容阅读
目的了解耐多药结核病患者不同分布特征及耐药情况,为耐多药结核病的防治提供参考。方法收集大庆市2009年1月-2012年10月期间在市疾控中心确诊的147例耐多药结核病患者耐药情况资料,根据患者不同年龄、居住地、性别等特征分析其耐多药发生情况。结果 147例耐多药结核病患者中,原发性耐多药患者33例,占22.45%(33/147);获得性耐多药患者114例,占77.6%(114/147)。原发耐多药以41~50岁组最高,占30.3%;获得性耐多药患者以41~50岁最高,占28.9%(33/114)。原发耐多药和获得性耐多药在不同年龄组的分布,差异无统计学意义(χ2=4.87,P=0.4321)。结论耐多药患者以青壮年为主,耐多药情况较严重,应加强对这一人群耐多药患者的治疗和监测,减少耐多药结核病的流行,降低其对公众的危害程度。同时提示老年耐多药结核病防治问题也不容忽视。
Objective To understand the different distribution and drug resistance of multidrug-resistant tuberculosis patients and provide references for the prevention and treatment of multidrug-resistant tuberculosis. Methods The data of 147 MDR-TB patients diagnosed in the CDC of Daqing City from January 2009 to October 2012 were collected. According to the characteristics of patients with different age, place of residence and gender, the multidrug resistance Happening. Results Of the 147 cases of MDR-TB, 33 cases were resistant to MDR, accounting for 22.45% (33/147); 114 cases were acquired MDR (77.6%, 114/147). The primary MDR was the highest in the group of 41-50 years old, accounting for 30.3%. The acquired MDR was the highest in 41-50 years (28.9%, 33/114). There was no significant difference in the distribution of primary MDR and acquired MDR in different age groups (χ2 = 4.87, P = 0.4321). Conclusion MDR patients are mainly young adults and multidrug-resistant patients are more serious. Treatment and monitoring of multidrug-resistant patients in this population should be strengthened to reduce the prevalence of MDR-TB and reduce their harm to the public. At the same time suggest that MDR-TB prevention and treatment in the elderly can not be ignored.